arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Corbus Pharmaceuticals Holdings, Inc.

CRBP Health Care Biotechnology: Pharmaceutical Preparations
$4.05
▼ -5.5% Today
as of Oct 23, 16:47 ET
Last 30 days -49.88% Sep 14 → Oct 23
$3.73 $4.90 $6.07 $7.23 $8.40 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$4.08
High
$4.08
Low
$3.93
Volume
$372,540
Avg Vol
$493,071
Mkt Cap
$123M
P/E (TTM)
—
Beta
—
52w High
$18.11
52w Low
$3.93
Div Yield
—
Shares Out
$19M

Recent Press Releases & News last 60 days · 7 items

Oct 22 · 12:00 PR GlobeNewswire
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
Sep 29 · 12:00 PR GlobeNewswire
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
Sep 17 · 13:00 Zacks
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?
▸ Show all 7 press releases & news Free account →

CRBP earnings at a glance

The options market is pricing a move of about ±5.7% after the report, a range of roughly $3.82 to $4.28 from today's $4.05. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±9.7% on average; after the most recent report on May 12, 2026 it moved +3.5%. That means options currently expect less movement than CRBP has typically delivered. CRBP beat the consensus EPS estimate in 2 of its last 4 reported quarters. Implied volatility is currently 48%. The share price of $4.05 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$3.93
$18
1% of range
Avg surprise (last 4)
-1.6%
Avg reaction (last 2)
-6.1%
50% positive
Latest IV / EM
48%
EM ±5.7% · $5 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-4.24$-3.39$-2.54$-1.68$-0.83 Actual $-4.24Actual $-2.05Actual $-2.27Actual $-0.83Actual $-0.90Actual $-1.15Actual $-1.39Est $-1.26Actual $-1.44Est $-1.55Actual $-1.90Est $-1.80Actual $-1.23Est $-1.26Actual $-1.81 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-35M$-30M$-25M$-20M$-14M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-1.81 — — — — financials
Tue May 12, 2026Mar/2026 $-1.23 $-1.26 +2.4% +11.5% +3.5% earnings
Wed Nov 12, 2025Sep/2025 $-1.90 $-1.80 -5.6% — — earnings
Tue Aug 5, 2025Jun/2025 $-1.44 $-1.55 +7.1% — — earnings
Tue May 6, 2025Mar/2025 $-1.39 $-1.26 -10.3% — -15.8% earnings
Mon Sep 30, 2024Sep 2024 $-1.15 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.90 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.83 — — — — financials
Sat Sep 30, 2023Sep 2023 $-2.27 — — — — financials
Fri Jun 30, 2023Jun 2023 $-2.05 — — — — financials
Fri Mar 31, 2023Mar 2023 $-4.24 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-36M$-24M—$-24M$-19M$-20M—$-16M
Net income$-35M$-23M—$-23M$-18M$-17M—$-14M
EPS (diluted)$-1.81$-1.23—$-1.90$-1.44$-1.39—$-1.15

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$23M$26M$28M$27M$20M$19M$17M$19M
Inventory————————
Total current assets$123M$144M$167M$108M$123M$137M$153M$161M
Total assets$127M$144M$168M$110M$125M$140M$156M$164M
Long-term debt————————
Total liabilities$25M$18M$21M$17M$14M$13M$13M$14M
Total equity$102M$126M$148M$92M$111M$127M$142M$150M

Implied volatility — last 90 days

34%107%180%253%326% Jun 07 — IV 119% · EM ±16.5%Jun 08 — IV 123% · EM ±16.2%Jun 09 — IV 130% · EM ±16.2%Jun 10 — IV 99% · EM ±11.7%Jun 11 — IV 93% · EM ±10.3%Jun 12 — IV 66% · EM ±6.7%Jun 15 — IV 91% · EM ±6.6%Jun 16 — IV 193% · EM ±11.4%Jun 17 — IV 164% · EM ±6.8%Jun 19 — IV 162% · EM ±35.7%Jun 22 — IV 40% · EM ±8.4%Jun 23 — IV 35% · EM ±7.1%Jun 24 — IV 64% · EM ±12.8%Jun 25 — IV 59% · EM ±11.5%Jun 26 — IV 145% · EM ±27.7%Jun 29 — IV 45% · EM ±7.9%Jun 30 — IV 46% · EM ±8.0%Jul 01 — IV 56% · EM ±9.4%Jul 02 — IV 53% · EM ±8.6%Jul 03 — IV 55% · EM ±8.6%Jul 06 — IV 56% · EM ±7.8%Jul 07 — IV 44% · EM ±5.9%Jul 08 — IV 58% · EM ±7.3%Jul 09 — IV 57% · EM ±6.7%Jul 10 — IV 65% · EM ±7.2%Jul 13 — IV 53% · EM ±4.4%Jul 14 — IV 46% · EM ±3.3%Jul 15 — IV 56% · EM ±3.3%Jul 20 — IV 150% · EM ±35.4%Jul 21 — IV 100% · EM ±23.2%Jul 22 — IV 151% · EM ±34.5%Jul 23 — IV 136% · EM ±30.6%Jul 24 — IV 210% · EM ±46.3%Jul 27 — IV 316% · EM ±66.1%Jul 28 — IV 261% · EM ±53.4%Jul 29 — IV 281% · EM ±56.4%Jul 30 — IV 282% · EM ±55.2%Jul 31 — IV 169% · EM ±32.3%Aug 03 — IV 146% · EM ±25.8%Aug 04 — IV 82% · EM ±14.1%Aug 05 — IV 147% · EM ±24.6%Aug 06 — IV 75% · EM ±12.1%Aug 07 — IV 91% · EM ±14.3%Aug 10 — IV 137% · EM ±19.0%Aug 11 — IV 111% · EM ±14.7%Aug 12 — IV 108% · EM ±13.6%Aug 13 — IV 99% · EM ±11.7%Aug 14 — IV 94% · EM ±10.4%Aug 17 — IV 160% · EM ±13.3%Aug 18 — IV 130% · EM ±9.4%Aug 19 — IV 140% · EM ±8.3%Aug 20 — IV 134% · EM ±5.6%Aug 24 — IV 106% · EM ±22.2%Aug 25 — IV 165% · EM ±33.8%Aug 26 — IV 145% · EM ±29.0%Aug 27 — IV 147% · EM ±28.8%Aug 28 — IV 122% · EM ±23.4%Aug 31 — IV 132% · EM ±23.4%Sep 01 — IV 143% · EM ±24.6%Sep 02 — IV 171% · EM ±28.5%Sep 03 — IV 162% · EM ±26.2%Sep 04 — IV 172% · EM ±26.9%Sep 07 — IV 194% · EM ±26.9%Sep 08 — IV 177% · EM ±23.4%Sep 09 — IV 181% · EM ±22.7%Sep 10 — IV 62% · EM ±7.3%Sep 11 — IV 230% · EM ±25.5%Sep 14 — IV 172% · EM ±14.3%Sep 15 — IV 187% · EM ±13.5%Sep 16 — IV 326% · EM ±19.3%Sep 21 — IV 85% · EM ±17.6%Sep 22 — IV 87% · EM ±17.8%Sep 23 — IV 97% · EM ±19.4%Sep 24 — IV 77% · EM ±15.1%Sep 25 — IV 80% · EM ±15.4%Sep 28 — IV 77% · EM ±13.7%Sep 29 — IV 137% · EM ±23.7%Sep 30 — IV 140% · EM ±23.5%Oct 01 — IV 195% · EM ±31.5%Oct 08 — IV 48% · EM ±5.7%

Sector peers

SPRB
Spruce Biosciences, Inc.
$129M $45.15+5.7%
AARD
Aardvark Therapeutics, Inc.
$115M $1.39-68.5%
LIXT
Lixte Biotechnology Holdings, Inc.
$115M $7.21+75.8%
GNLX
Genelux Corporation
$114M $2.00-3.4%
PMVP
PMV Pharmaceuticals, Inc.
$132M $1.27-6.6%
PYPD
PolyPid Ltd.
$109M $5.25+3.5%

CRBP earnings FAQ

What is CRBP's expected move for earnings?

Options currently price a move of about ±5.7%, or $0.23 per share either way from $4.05.

How does CRBP stock usually react to earnings?

Across the last 2 reports the average next-day move was ±9.7%, up 1 times and down 1 times.

What is CRBP's implied volatility?

CRBP's at-the-money implied volatility is about 48% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in